AlloVir
Julie Mabalot Luk has extensive work experience in the pharmaceutical industry. Julie currently serves as the Director of Clinical Operations and Early Portfolio Management at AlloVir since August 2021. Prior to that, they worked at Merck for 16 years, starting as an Associate Principal Scientist in Early Stage Development Operations in August 2005 and leaving in July 2021. Julie also worked at SST Corporation as a Regulatory Affairs Specialist from February 2004 to August 2005, and at Schering-Plough Research Institute as a Clinical Information Specialist from June 2003 to January 2004.
Julie Mabalot Luk has a graduate certificate in Clinical Research Administration from The George Washington University School of Medicine and Health Sciences. Additionally, they attended Rutgers University - Newark, but no degree or field of study is specified.
This person is not in any offices
AlloVir
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.